[Effect of Morinda lucida Benth. (Rubiaceae) and Newbouldia leavis P. Beauv. (Bignoniaceae) on sickling of red blood cells].
The purpose of this study was to evaluate the In vitro anti-sickling activity of two plants widely used for treatment of sickle cell disease in Togo, i.e., Morinda lucida et Newbouldia leavis. A concentration-dependent decrease in the rate of sickling was observed after incubation of red blood cells with plant extracts and 2% sodium metabisulfite as compared to incubation with 0.9% NaCl. On samples with a SS blood genotype the inhibition rate of Morinda lucida was 17.30% at a concentration of 1 mg/ml and 92.31% at a concentration of 30 mg/ml. On samples with an AS blood genotype, the inhibition rate of Morinda lucida 48.10% at a concentration of 1 mg/ml and 99.34% at a concentration of 30 mg/ml. Using Newbouldia leavis the inhibition rates at concentrations of 1 mg/ml and 30 mg/ml were 15.66% and 90.42% respectively on samples with a SS blood genotype and 64.03% and 99.02% respectively on samples with an AS blood genotype. The study protocol appeared to be adequate for both SS and AS blood genotypes since the Pearson correlation coefficient between rates measured on the two types of samples was 0.92 for Newuboulida and 0.89 for Morinda. These findings show that these two plants have clear-cut in vitro anti-sickling activity and support their use in traditional medicine.
Joppa
K M
KM
Centre de Recherche et de Formation sur les Plantes Médicinales, Département de Physiologie Animale, Faculté des Sciences, Université de Lomé, BP 1515, Lomé, Togo.
Vovor
A
A
Eklu-Gadegbeku
K
K
Agbonon
A
A
Aklikokou
K
K
Gbeassor
M
M
D000755:Anemia, Sickle Cell / Q000097:blood* / Q000188:drug therapy; D000818:Animals; D000986:Antisickling Agents / Q000494:pharmacology; D029402:Bignoniaceae; D004912:Erythrocytes / Q000187:drug effects*; D005838:Genotype; D006801:Humans; D066298:In Vitro Techniques; D032066:Morinda; D008517:Phytotherapy; D051381:Rats; D017208:Rats, Wistar
D000986:Antisickling Agents